Analysts Revise Forecasts for Gossamer Bio (GOSS) Amid Uncertain Regulatory Environment

Gossamer Bio, Inc. (NASDAQ:GOSS) is included in our list of the 10 most active penny stocks to buy.

As of March 16, 2026, Gossamer Bio, Inc. (NASDAQ:GOSS) has support from 44% of analysts who maintain a “Buy” rating for the stock. The consensus price target of $1.00 indicates an upside potential of 117.39%.

Amid an uncertain regulatory environment, analysts recently revised their forecasts for Gossamer Bio, Inc. (NASDAQ:GOSS)’s primary therapy, seralutinib. This therapy is being developed for pulmonary arterial hypertension (PAH).

H.C. Wainwright & Co. maintained a “Buy” rating but lowered its price target for Gossamer Bio, Inc. (NASDAQ:GOSS) from $10 to $5 on March 6, 2026. A more cautious outlook on the program’s development prospects led the firm to lower its probability of success for seralutinib in PAH from 70% to 50%.

Additionally, on March 5, 2026, Oppenheimer & Co. reiterated its “Outperform” rating while lowering its price target from $12 to $3. While citing short-term regulatory uncertainties, the firm pointed out that a June FDA interaction, Week 48 results, and future CT FRI substudy data might help reduce risk in seralutinib’s approval pathway and potentially lead to a re-rating in the shares.

Gossamer Bio, Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company developing treatments for immunology, inflammation, and oncology, notably GB001 for eosinophilic asthma. Established in 2015, it is based in San Diego, California.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.